HIF1A and laryngotracheoesophageal cleft: To confirm that HIF-1α degradation is a key mechanism underlying the efficacy of AsA treatment in the IP + LC model, IP + LC models treated with or without AsA (AsA [ +] and AsA [−] groups) were compared with the IP + LC model treated with both AsA and the HIF-1α activator DMOG (AsA + HIF-1α-ac group) (Fig. 6A).